List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2689150/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney International, 2009, 75, 976-981.	5.2	266
2	A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opinion on Investigational Drugs, 2011, 20, 897-915.	4.1	212
3	Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney International, 2001, 60, 1885-1892.	5.2	207
4	Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 2010, 95, 505-508.	3.5	159
5	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Journal of Clinical Investigation, 2000, 105, 643-651.	8.2	158
6	Antibody blockade of TNF-Î \pm reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney International, 2005, 67, 1812-1820.	5.2	128
7	Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney International, 2009, 76, 199-206.	5.2	118
8	Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surgery for Obesity and Related Diseases, 2013, 9, 559-568.	1.2	117
9	Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin–angiotensin–aldosterone system inhibition. Kidney International, 2011, 80, 851-860.	5.2	110
10	P2X7 Deficiency Attenuates Renal Injury in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1275-1281.	6.1	105
11	Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes. Diabetes Care, 2009, 32, 1137-1142.	8.6	104
12	Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine, 2009, 47, 37-42.	3.2	99
13	Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrology Dialysis Transplantation, 2004, 19, 2761-2768.	0.7	94
14	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrology Dialysis Transplantation, 2015, 30, 1185-1192.	0.7	94
15	Urinary monocyte chemoattractant protein-1 in renal disease. Clinica Chimica Acta, 2011, 412, 2022-2030.	1.1	83
16	A Spleen Tyrosine Kinase Inhibitor Reduces the Severity of Established Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2010, 21, 231-236.	6.1	74
17	Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrology Dialysis Transplantation, 2006, 22, 386-395.	0.7	73
18	Inhibition of p38 Mitogen-Activated Protein Kinase Is Effective in the Treatment of Experimental Crescentic Glomerulonephritis and Suppresses Monocyte Chemoattractant Protein-1 but Not IL-1β or IL-6. Journal of the American Society of Nephrology: JASN, 2007, 18, 1167-1179.	6.1	70

#	Article	IF	CITATIONS
19	Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients. Journal of Immunology, 2012, 189, 3751-3758.	0.8	65
20	Hyperglycemia-induced Renal P2X7 Receptor Activation Enhances Diabetes-related Injury. EBioMedicine, 2017, 19, 73-83.	6.1	64
21	Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney International, 1995, 48, 1738-1746.	5.2	58
22	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Reports Medicine, 2020, 1, 100137.	6.5	56
23	P2X7 receptor-mediated Nlrp3-inflammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis. Journal of Leukocyte Biology, 2013, 93, 127-134.	3.3	50
24	Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats. Kidney International, 2015, 88, 1079-1087.	5.2	48
25	Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN. Journal of the American Society of Nephrology: JASN, 2014, 25, 2291-2302.	6.1	46
26	Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney International, 1999, 55, 1319-1326.	5.2	45
27	Differential expression of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 in experimental glomerulonephritis. Kidney International, 1996, 49, 715-721.	5.2	44
28	Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7responses. Journal of Leukocyte Biology, 2009, 85, 978-986.	3.3	43
29	Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. Kidney International, 2020, 98, 420-435.	5.2	40
30	Fostamatinib disodium. Drugs of the Future, 2011, 36, 273.	0.1	40
31	Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6. Kidney International, 1997, 52, 1313-1320.	5.2	39
32	Arginase AI Is Upregulated in Acute Immune Complex-Induced Inflammation. Biochemical and Biophysical Research Communications, 1998, 247, 84-87.	2.1	39
33	Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor. Kidney International, 1997, 52, 1224-1231.	5.2	38
34	Label Free Detection of Sensitive Mid-Infrared Biomarkers of Glomerulonephritis in Urine Using Fourier Transform Infrared Spectroscopy. Scientific Reports, 2017, 7, 4601.	3.3	38
35	High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. Journal of Rheumatology, 2019, 46, 285-293.	2.0	38
36	Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions. Journal of Immunology, 2015, 195, 2343-2352.	0.8	37

#	Article	IF	CITATIONS
37	Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. CKJ: Clinical Kidney Journal, 2017, 10, sfw116.	2.9	37
38	Renal Tubular Cell Mitochondrial Dysfunction Occurs Despite Preserved Renal Oxygen Delivery in Experimental Septic Acute Kidney Injury. Critical Care Medicine, 2018, 46, e318-e325.	0.9	36
39	The Role of Continuous Ambulatory Peritoneal Dialysis in End-Stage Renal Failure Due to Multiple Myeloma. American Journal of Kidney Diseases, 1990, 16, 216-223.	1.9	34
40	Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney International, 2015, 88, 52-60.	5.2	34
41	Spleen tyrosine kinase inhibition is an effectiveÂtreatment for established vasculitis inÂaÂpre-clinical model. Kidney International, 2020, 97, 1196-1207.	5.2	34
42	The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation. Nephrology Dialysis Transplantation, 2013, 28, iv73-iv82.	0.7	33
43	Primary IgA nephropathy: current challenges and future prospects. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 137-148.	1.8	32
44	P2 purinoceptors: Renal pathophysiology and therapeutic potential. Clinical Nephrology, 2012, 78, 154-163.	0.7	31
45	Modulation of antibody-mediated glomerular injury in vivo by interleukin-6. Kidney International, 1993, 44, 967-973.	5.2	29
46	Interleukin-11 Attenuates Nephrotoxic Nephritis in Wistar Kyoto Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 2310-2320.	6.1	28
47	Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney International, 2021, 100, 1316-1324.	5.2	26
48	Sodium and water handling after gastric bypass surgery in a rat model. Surgery for Obesity and Related Diseases, 2011, 7, 68-73.	1.2	25
49	Purinergic signaling in inflammatory renal disease. Frontiers in Physiology, 2013, 4, 194.	2.8	24
50	Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction. Nephrology Dialysis Transplantation, 2014, 29, 1350-1361.	0.7	24
51	Genetic Loci Modulate Macrophage Activity and Glomerular Damage in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2010, 21, 1136-1144.	6.1	23
52	Dialysate Cytokine Levels do not Predict Encapsulating Peritoneal Sclerosis. Peritoneal Dialysis International, 2014, 34, 594-604.	2.3	23
53	Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells. American Journal of Physiology - Renal Physiology, 1998, 274, F473-F480.	2.7	21
54	CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis. European Journal of Clinical Investigation, 2010, 40, 1067-1073.	3.4	21

#	Article	IF	CITATIONS
55	Genes Expressed by Both Mesangial Cells and Bone Marrow–Derived Cells Underlie Genetic Susceptibility to Crescentic Glomerulonephritis in the Rat. Journal of the American Society of Nephrology: JASN, 2007, 18, 1816-1823.	6.1	20
56	P2X ₇ receptor antagonism ameliorates renal dysfunction in a rat model of sepsis. Physiological Reports, 2018, 6, e13622.	1.7	19
57	Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy. Seminars in Nephrology, 2018, 38, 496-503.	1.6	19
58	<scp>ATP</scp> and arterial calcification. European Journal of Clinical Investigation, 2013, 43, 405-412.	3.4	18
59	P2 receptors in renal pathophysiology. Purinergic Signalling, 2009, 5, 513-520.	2.2	17
60	TESTING Corticosteroids in IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 158-160.	4.5	16
61	Urine Proteomics and Biomarkers in Renal Disease. Nephron Experimental Nephrology, 2011, 119, e1-e7.	2.2	15
62	Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy. CKJ: Clinical Kidney Journal, 2019, 12, 232-238.	2.9	14
63	Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?. Nephrology Dialysis Transplantation, 2020, 35, 198-203.	0.7	12
64	UP-REGULATION OF TYPE 1 PLASMINOGEN ACTIVATOR INHIBITOR MESSENGER RNA WITH THROMBOTIC CHANGES IN RENAL GRAFTS1. Transplantation, 1996, 61, 684-689.	1.0	12
65	Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opinion on Investigational Drugs, 2006, 15, 1353-1369.	4.1	11
66	B-cell-targeted therapy in adult glomerulonephritis. Expert Opinion on Biological Therapy, 2013, 13, 1691-1706.	3.1	11
67	Modification of an aggressive model of Alport Syndrome reveals early differences in disease pathogenesis due to genetic background. Scientific Reports, 2019, 9, 20398.	3.3	11
68	Effect of IL-11 on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats. Journal of Nephrology, 2011, 24, 106-111.	2.0	11
69	Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort. Scientific Reports, 2018, 8, 53.	3.3	9
70	Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis. Journal of Nephrology, 2007, 20, 340-9.	2.0	8
71	P2X7 Receptor Stimulation Is Not Required for Oxalate Crystal-Induced Kidney Injury. Scientific Reports, 2019, 9, 20086.	3.3	7
72	Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS). Kidney International Reports, 2019, 4, 1342-1348.	0.8	6

#	Article	IF	CITATIONS
73	SYK inhibition in experimental autoimmune vasculitis and its glomerular expression in ANCA-associated vasculitis. Lancet, The, 2014, 383, S72.	13.7	5
74	CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuloepithelial cells. BMC Nephrology, 2016, 17, 139.	1.8	5
75	Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. Scientific Reports, 2022, 12, 3330.	3.3	5
76	Aversive effects of subcutaneously injected vasopressin in the rat: independence of the ascending dorsal noradrenergic bundle. Brain Research, 1985, 337, 133-137.	2.2	4
77	Fragmentation of filtered proteins and implications for glomerular protein sieving in Fanconi syndrome. Kidney International, 2002, 62, 349.	5.2	4
78	Impact of kidney size on mortality in diabetic patients receiving peritoneal dialysis. Scientific Reports, 2021, 11, 8203.	3.3	4
79	Characterisation of an enhanced preclinical model of experimental MPOâ€ANCA autoimmune vasculitis. Journal of Pathology, 2021, 255, 107-119.	4.5	4
80	Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. Kidney International, 2018, 94, 926-936.	5.2	3
81	Glomerulonephritis and autoimmune vasculitis are independent of <scp>P2RX7</scp> but may depend on alternative inflammasome pathways. Journal of Pathology, 2022, 257, 300-313.	4.5	3
82	Impact of kidney size on the outcome of diabetic patients receiving hemodialysis. PLoS ONE, 2022, 17, e0266231.	2.5	2
83	Plasmacytoma-Like Posttransplant Lymphoproliferative Disease in a Disused Arteriovenous Fistula: The Importance ofÂHistopathology. Kidney International Reports, 2019, 4, 749-755.	0.8	1
84	Masked crystalline light chain tubulopathy and podocytopathy with focal segmental glomerulosclerosis: a rare MGRSâ€associated renal lesion. Histopathology, 2021, 79, 265-268.	2.9	1
85	Interdependent expression of P2X receptors in the mouse kidney: P2X4â€P2X7 receptor "crossâ€ŧalk― FASE Journal, 2013, 27, 884.3.	B _{0.5}	1
86	Renal cytokines and biochemical profiles after bariatric surgery. Surgery for Obesity and Related Diseases, 2010, 6, 228-229.	1.2	0
87	Currently available and potential future treatment options for IgA nephropathy. Expert Opinion on Orphan Drugs, 2013, 1, 625-635.	0.8	0
88	Is P2X7 a potential therapeutic target in the treatment of retinal diseases: an animal study. Lancet, The, 2016, 387, S91.	13.7	0
89	211. A NOVEL P2X7 KNOCKOUT RAT IS NOT PROTECTED FROM EXPERIMENTAL GLOMERULONEPHRITIS OR VASCULITIS. Rheumatology, 2019, 58, .	1.9	0
90	214. THE EFFECT OF P2X7 ANTAGONISM ON NEPHROTOXIC NEPHRITIS. Rheumatology, 2019, 58, .	1.9	0

#	Article	IF	CITATIONS
91	Dr. Kang, <i>et al,</i> reply. Journal of Rheumatology, 2019, 46, 1244.2-1244.	2.0	Ο
92	Dr. Kang, <i>et al</i> reply. Journal of Rheumatology, 2019, 46, 866.2-867.	2.0	0